1. Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome
- Author
-
Jean Combalbert, Dirk Timmerman, Bart C.J.M. Fauser, Joop S.E. Laven, Graeme Fraser, Hamid R. Hoveyda, Axelle Pintiaux, Barbara Obermayer-Pietsch, Steven Ramael, Georg Griesinger, Christopher Lademacher, and Obstetrics & Gynecology
- Subjects
0301 basic medicine ,medicine.medical_specialty ,ANTI-MULLERIAN HORMONE ,Endocrinology, Diabetes and Metabolism ,Clinical Biochemistry ,Context (language use) ,GRANULOSA ,Placebo ,Biochemistry ,Gastroenterology ,B RECEPTOR ,law.invention ,neurokinin B ,kisspeptin ,Anovulation ,Endocrinology & Metabolism ,03 medical and health sciences ,HORMONE PULSE-GENERATOR ,0302 clinical medicine ,Endocrinology ,Randomized controlled trial ,SDG 3 - Good Health and Well-being ,law ,Internal medicine ,medicine ,gonadotropin-releasing hormone ,ESTRADIOL ,Science & Technology ,030219 obstetrics & reproductive medicine ,business.industry ,LIFE QUESTIONNAIRE PCOSQ ,neurokinin 3 receptor ,Biochemistry (medical) ,Hyperandrogenism ,dynorphin A neurons ,WOMEN ,Testosterone (patch) ,LH SURGE ,medicine.disease ,Polycystic ovary ,030104 developmental biology ,Tolerability ,polycystic ovary syndrome ,GONADOTROPIN-SECRETION ,business ,Life Sciences & Biomedicine - Abstract
Context Polycystic ovary syndrome (PCOS), a highly prevalent endocrine disorder characterized by hyperandrogenism, is the leading cause of anovulatory infertility. Objective This proof-of-concept study evaluated clinical efficacy and safety of the neurokinin 3 (NK3) receptor antagonist fezolinetant in PCOS. Methods This was a phase 2a, randomized, double-blind, placebo-controlled, multicenter study (EudraCT 2014-004409-34). The study was conducted at 5 European clinical centers. Women with PCOS participated in the study. Interventions included fezolinetant 60 or 180 mg/day or placebo for 12 weeks. The primary efficacy end point was change in total testosterone. Gonadotropins, ovarian hormones, safety and tolerability were also assessed. Results Seventy-three women were randomly assigned, and 64 participants completed the study. Adjusted mean (SE) changes in total testosterone from baseline to week 12 for fezolinetant 180 and 60 mg/day were −0.80 (0.13) and −0.39 (0.12) nmol/L vs −0.05 (0.10) nmol/L with placebo (P .10). Fezolinetant was well tolerated. Conclusion Fezolinetant had a sustained effect to suppress hyperandrogenism and reduce the LH-to-FSH ratio in women with PCOS.
- Published
- 2021